期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 84, 期 1, 页码 47-58出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2012.02.004
关键词
Non-small cell lung cancer (NSCLC); Vascular endothelial growth factor (VEGF); Platelet-derived growth factor (PDGF); Fibroblast growth factor (FGF); Multitargeted kinase inhibitors; Anti-angiogenic agents
资金
- Boehringer Ingelheim Pharmaceuticals, Inc (BIPI)
Increasing understanding of the molecular abnormalities driving cell growth and proliferation has resulted in extensive research into molecularly targeted therapies. Angiogenesis is an appealing target for the treatment of non small cell lung cancer (NSCLC). Bevacizumab, a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), is already approved for the treatment of NSCLC. Many other anti-angiogenic agents under development form the focus of this review. A variety of agents, including sorafenib, sunitinib, cediranib, axitinib, motesanib, linifinib and brivanib inhibit VEGF in addition to either platelet derived growth factor (PDGF), or fibroblast derived growth factor (FGF). To date, none of these agents in combination with chemotherapy have resulted in improvements in overall survival for patients with advanced NSCLC. Triple angiokinase inhibitors, which inhibit VEGF, PDGF and FGF, have potential to improve the therapeutic outcomes for patients with NSCLC. However, there is a need for identification of appropriate biomarkers to improve patient selection and identify those patients benefiting from anti-angiogenesis therapy. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据